Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement

被引:98
作者
Contois, John H. [1 ]
Warnick, G. Russell [2 ]
Sniderman, Allan D. [3 ]
机构
[1] Maine Stand Co, Windham, ME 04062 USA
[2] Hlth Diagnost Lab, Richmond, VA USA
[3] McGill Univ, Ctr Hlth, Mike Rosenbloom Lab Cardiovasc Res, Montreal, PQ, Canada
关键词
Apolipoprotein B; Cardiovascular disease; HDL cholesterol; LDL cholesterol; Non-HDL cholesterol; EDUCATION-PROGRAM RECOMMENDATIONS; CHEMISTRY STANDARDIZATION PROJECT; LDL-CHOLESTEROL; HOMOGENEOUS ASSAYS; DISEASE RISK; INTERNATIONAL FEDERATION; MULTICENTER EVALUATION; CARDIOVASCULAR EVENTS; MYOCARDIAL-INFARCTION; CLINICAL-PERFORMANCE;
D O I
10.1016/j.jacl.2011.05.004
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
There is little understanding of the reliability of laboratory measurements among clinicians. Low-density lipoprotein cholesterol (LDL-C) measurement is the cornerstone of cardiovascular risk assessment and prevention, but it is fraught with error. Therefore, we have reviewed issues related to accuracy and precision for the measurement of LDL-C and the related markers non-high-density lipoprotein cholesterol (non-HDL-C) and apolipoprotein B. Despite the widespread belief that LDL-C is standardized and reproducible, available data suggest that results can vary significantly as the result of methods from different manufacturers. Similar problems with direct HDL-C assays raise concerns about the reliability of non-HDL-C measurement. The root cause of method-specific bias relates to the ambiguity in the definition of both LDL and HDL, and the heterogeneity of LDL and HDL particle size and composition. Apolipoprotein B appears to provide a more reliable alternative, but assays for it have not been as rigorously tested as direct LDL-C and HDL-C assays. (C) 2011 National Lipid Association. All rights reserved.
引用
收藏
页码:264 / 272
页数:9
相关论文
共 43 条
[1]
BACHORIK PS, 1995, CLIN CHEM, V41, P1414
[2]
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel [J].
Barter, PJ ;
Ballantyne, CM ;
Carmena, R ;
Cabezas, MC ;
Chapman, MJ ;
Couture, P ;
De Graaf, J ;
Durrington, PN ;
Faergeman, O ;
Frohlich, J ;
Furberg, CD ;
Gagne, C ;
Haffner, SM ;
Humphries, SE ;
Jungner, I ;
Krauss, RM ;
Kwiterovich, P ;
Marcovina, S ;
Packard, CJ ;
Pearson, TA ;
Reddy, KS ;
Rosenson, R ;
Sarrafzadegan, N ;
Sniderman, AD ;
Stalenhoef, AF ;
Stein, E ;
Talmud, PJ ;
Tonkin, AM ;
Walldius, G ;
Williams, KMS .
JOURNAL OF INTERNAL MEDICINE, 2006, 259 (03) :247-258
[3]
Is directly measured low-density lipoprotein clinically equivalent to calculated low-density lipoprotein? [J].
Baruch, Lawrence ;
Agarwal, Sanjay ;
Gupta, Bhanu ;
Haynos, Ann ;
Johnson, Swapna ;
Kelly-Johnson, Katelyn ;
Eng, Calvin .
JOURNAL OF CLINICAL LIPIDOLOGY, 2010, 4 (04) :259-264
[4]
Bayer P, 2005, ANN BIOL CLIN-PARIS, V63, P27
[5]
Accuracy of calculated serum low-density lipoprotein cholesterol for the assessment of coronary heart disease risk in NIDDM patients [J].
Branchi, A ;
Rovellini, A ;
Torri, A ;
Sommariva, D .
DIABETES CARE, 1998, 21 (09) :1397-1402
[6]
Lipoprotein management in patients with cardiometabolic risk - Consensus conference report from the American diabetes association and the American college of cardiology foundation [J].
Brunzell, John D. ;
Davidson, Michael ;
Furberg, Curt D. ;
Goldberg, Ronald B. ;
Howard, Barbara V. ;
Stein, James H. ;
Witztum, Joseph L. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (15) :1512-1524
[7]
Centers for Disease Control and Prevention (CDC), LAB QUAL ASS STAND P
[8]
COHN JS, 1988, J LIPID RES, V29, P469
[9]
Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices [J].
Contois, John H. ;
McConnel, Joseph P. ;
Sethi, Amar A. ;
Csako, Gyorgy ;
Devaraj, Sridevi ;
Hoefner, Daniel M. ;
Warnick, Russell .
CLINICAL CHEMISTRY, 2009, 55 (03) :407-419
[10]
COOPER GR, 1994, CLIN CHEM, V40, P227